Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"In addition, on December 13, 2006, Mr. H. Leigh Severance and Mr. Javier W. Baz resigned as members of the Board of Directors effective 5:00 p.m. on December 13, 2006".
This is the most important part of that report.
Lifevantage Corporation Announces CEO and Board Changes
15 December 2006, 2:58pm ET
DENVER, Dec 15, 2006 (BUSINESS WIRE) --
Lifevantage Corporation (BB:LFLT), maker of Protandim(R), today announced that Mr. Stephen K. Onody has resigned as Chief Executive Officer and as a member of the Board of Directors effective December 15, 2006. Mr. Onody will provide the Board of Directors and Company with consulting services during the three months following his resignation in order to ensure a smooth transition.
The Board of Directors has appointed Mr. John Van Heuvelen as the Company's interim Chief Executive Officer to fill the vacancy created by Mr. Onody's departure. Mr. Van Heuvelen has been a member of the Board of Directors since August 2005 and Chairman of the Board since September 2006. Mr. Van Heuvelen spent 13 years with Morgan Stanley and Dean Witter Reynolds in various executive positions in the mutual fund, unit investment trust, and municipal bond divisions, including serving as president of Morgan Stanley Dean Witter Trust Company from 1993 until 1999. Since 1999, Mr. Van Heuvelen has been a private equity investor based in Denver, Colorado, investing primarily in telecommunications and technology firms.
In addition, on December 13, 2006, Mr. H. Leigh Severance and Mr. Javier W. Baz resigned as members of the Board of Directors effective 5:00 p.m. on December 13, 2006.
"It has been my sincere pleasure to serve as Chief Executive Officer of Lifevantage," said Mr. Onody. "I am extremely proud of the many accomplishments of the Company and the tremendous team that has been assembled to take the Company to the next level."
"Steve has built a great team in the past year and the Board of Directors and the Company thank him for his service," said John Van Heuvelen, Chairman of the Board of Directors and interim Chief Executive Officer. "While we regret that Steve will no longer be with us, we remain excited about the future and the potential of Lifevantage."
About Protandim(R)
Mentioned Last Change
LFLT 0.61 0.06dollars or (8.95%)
Protandim(R) is a patent-pending dietary supplement that increases the body's natural antioxidant protection by inducing two protective enzymes, superoxide dismutase (SOD) and catalase (CAT). These naturally occurring enzymes become overwhelmed by free radicals as we get older. Oxidative stress (cell damage caused by free radicals) occurs as a person ages, when subjected to environmental stresses or as an associated factor in certain illnesses. TBARS are laboratory markers for oxidative stress in the body. Data from a peer-reviewed, published scientific study in men and women, sponsored by Lifevantage, shows that after 30 days of taking Protandim(R), the level of circulating TBARS decreased an average of 40 percent, with this decrease shown to be maintained at 120 days. Protandim(R) strengthens a person's defenses against oxidative stress by increasing the body's natural antioxidant enzymes. For more information, please visit the Protandim(R) product web site at www.protandim.com.
About Lifevantage Corporation
Lifevantage Corporation markets Protandim(R). Lifevantage is committed to helping people achieve health and wellness for life. For more information, please visit the Company's web site at www.Lifevantage.com.
Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, applicable common law and Securities and Exchange Commission rules. The Company uses the words "anticipate," "believe," "could," "should," "estimate," "expect," "intend," "may," "predict," "project," "plan," "target" and similar terms and phrases, including references to assumptions, to identify forward-looking statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties are difficult to predict accurately and may be beyond the control of the Company. The following factors are among those that may cause actual results to differ materially from our forward-looking statements: government regulators and regulations could adversely affect our business; future laws or regulations may hinder or prohibit the production or sale of our existing product and any future products; unfavorable publicity could materially hurt our business and the value of your investment; and the Company's ability to protect our intellectual property rights and the value of our product. These and other additional risk factors and uncertainties are discussed in greater detail in the Company's Annual Report on Form 10-KSB under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission. Forward-looking statements made by the Company in this news release or elsewhere speak only as of the date made. New uncertainties and risks come up from time to time, and it is impossible for the Company to predict these events or how they may affect the Company. The Company has no duty to, and does not intend to, update or revise the forward-looking statements in this news release after the date it is issued. In light of these risks and uncertainties, investors should keep in mind that the results, events or developments disclosed in any forward-looking statement made in this news release may not occur.
SOURCE: Lifevantage Corporation
Lifevantage Corporation
John Van Heuvelen, CEO, 720-488-1711
Gerald J. Houston, CFO, 720-488-1711
Fax: 303-565-8700
Copyright Business Wire 2006
Very bad management is what keeps this stock down.
Nibbling low vol consolidation. Head and shoulders bottom after great news.
CVS -- Booya Baby !! Read this PR Below
Lifeline Therapeutics, Inc. Announces Distribution of Protandim(R) in CVS/Pharmacy Stores Nationwide
Business Editors / Healthcare Editors
DENVER--(BUSINESS WIRE)--July 17, 2006-- Lifeline Therapeutics, Inc. (OTCBB: LFLT) today announced that Protandim(R) will be carried in CVS/pharmacy stores nationwide beginning in August. Protandim, a dietary supplement clinically proven to increase the body's natural antioxidant defenses and combat oxidative stress, will be sold at more than 6,100 locations in the CVS drugstore chain throughout the U.S., including the Sav-on and Osco stores recently acquired by CVS.
"By making Protandim available at CVS/pharmacy, we've greatly expanded our reach and are able to offer more customers the cellular health and healthy aging benefits of this fundamentally new approach to antioxidant therapy," said Stephen Onody, Lifeline Therapeutics CEO. "Through the CVS partnership, the availability of Protandim will be significantly increased."
As a part of the launch, CVS/pharmacy will co-market Protandim through a variety of initiatives, including national print advertisements in over 800 publications, in-store signage, and off-shelf merchandising. Lifeline also plans to offer a Continuing Medical Education program to CVS pharmacists.
About Protandim(R)
Protandim(R) is a patent-pending dietary supplement that increases the body's natural antioxidant protection by inducing two protective enzymes, superoxide dismustase (SOD) and catalase (CAT). These naturally occurring enzymes simply become overwhelmed by free radicals as we get older. Oxidative stress (cell damage caused by free radicals) occurs as a person ages, when subjected to environmental stresses or as an associated factor in certain illnesses. TBARS are laboratory markers for oxidative stress in the body. New data from a scientific study in men and women show that after 30 days of taking Protandim(R), the level of circulating TBARS decreased an average of 40 percent, with this decrease shown to be maintained at 120 days. Protandim(R) strengthens a person's defenses against oxidative stress by increasing the body's natural antioxidant enzymes. For more information, please visit the Protandim(R) product web site at http://www.protandim.com.
About Lifeline Therapeutics, Inc.
Lifeline Therapeutics, Inc. markets Protandim(R). Lifeline Therapeutics is committed to helping people achieve health and wellness for life. For more information, please visit the Company's web site at http://www.lifelinetherapeutics.com.
About CVS/pharmacy
CVS/pharmacy, America's largest retail pharmacy, is committed to serving the healthcare needs of all customers by being the easiest pharmacy for customers to use, both in its 6,100+ stores and online at CVS.com. General information about CVS is available at http://investor.cvs.com, as well as http://www.cvs.com/pressroom.
Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable common law. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Other important factors that the Company believes might cause such differences include the Company's limited cash flow and the rapid development of technology, lack of liquidity for the Company's common stock, working capital shortages, the length of time for scientific advances to reach the market (if they ever reach the market), among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company's filings with the Securities and Exchange Commission.
KEYWORD: NORTH AMERICA COLORADO UNITED STATES INDUSTRY KEYWORD: HEALTH ALTERNATIVE MEDICINE PHARMACEUTICAL RETAIL SPECIALTY PRODUCT/SERVICE SOURCE: Lifeline Therapeutics, Inc.
CONTACT INFORMATION: Lifeline Therapeutics, Inc. Stephen K. Onody, 720-488-1711 or Gerald J. Houston, 720-488-1711 Fax: 303-565-8700 or LeGrand Hart Erin Ragan, 303-298-8470 or Hannah Shawcross, 303-298-8470 Fax: 303-298-8570
I am not having problems with RB, but I looked for a message board for LFLT on IHub a long time ago - why doesn't it show up under the board listings (I searched by company name and by ticker symbol)?
This is an interview with gerentologist Aubrey de Grey on GMTV's Good Morning.
New Scientific Data Demonstrate Protandim(R) Improves the Body's Natural Ability to Reduce Oxidative Stress by Increasing Activity of Antioxidant Enzymes
DENVER, Jan. 17 /PRNewswire-FirstCall/ -- Lifeline Therapeutics, Inc. (OTC Bulletin Board: LFLT - News) announced data from a human study just published in the scientific journal, Free Radical Biology & Medicine (Jan. 15, 2006), demonstrated Protandim® was able to reduce oxidative stress in men and women.
In this study, before starting Protandim®, study participants, who ranged in age from 20 to 78, showed a strong age-related increase in TBARS. After 30 days of taking Protandim®, a 40 percent average decrease in TBARS was seen, and the age-related increase was eliminated. By 120 days of supplementation, Protandim® also significantly increased activity of SOD and CAT antioxidant enzymes by 30 percent and 54 percent, respectively.
No other antioxidant can prove this claim. Here is a link to the news release.
http://biz.yahoo.com/prnews/060117/cgtu054.html?.v=38
I've been taking protandim since June 10th. I haven't had one sick day since that time. I think Protandim is a great breakthrough!
nobody interested in lflt?
i went to a local gnc in westchester county, new york. i visited the store specifically to ask how the product has been moving. this particular gnc store had moved its last remaining bottle placed to the checkout area, where, as the salesperson commented, the hot items are kept. i then asked how many he had sold, and his reply was two in two weeks. that doesn't sound like a hot item to me; although, he was arabic, and i'm not sure that i completely understood him.
the same salesperson said that the company, lifeline, needs to make a better effort to market its product. he had some persons calling the store to make sure that they carried the product, but he sees greater sales only through increased advertising. though this was only one salesperson, he did seem rather optimistic about future sales. i don't know. i would like to visit some other gnc stores.
when does the quarterly come out? with so few shares outstanding (20 million), this stock could jump... and jump greatly quickly.
thank you for your input. i really like protandim better every day. i started june 10. it seems like a date i will always remember. as far as growing hair, i think something that is working for me is the combination of protandim and nox3 (which is arginine). the protandim promotes sod and the nox3 promotes nitric oxcide.
muscle pain and range of motion is a topic that's always on my mind. i'm 51 yr old male. i train in hung gar kung fu every day. i need flexability. i started the nox3 7 months ago. at that time i felt a slight improvment in flexabilty. so far i haven't noticed any additional flexability from the protandim, but it's possible that muscle pain might be a little less. of course this could get better after more time. i don't think that my old beat up body has had time to respond fully yet. i useally try a suppliment for at least a year to decide if i like it but because of the libido improvment alone i will keep taking it.
biknut
I have noticed elevated libido, however I can only hope for the return of long-gone hair, mostly gone.
Also, I have noticed a lack of muscle pain and a definite improvement in range of motion. I think the sports industry is going to discover Protandim and this will really boost the name recognition as well as the bottom line.
I'm in @ 11.50
good luck
i have been taking protandim for more than a month. this stuff is GREAT. so far i can tell two things that are happening. my hair is growing back and my libido is much improved. i'm planning to buy some stock because i think this is really big, and i think the company will be big too.
Antioxidants
URL of this page: http://www.nlm.nih.gov/medlineplus/antioxidants.html
Latest News
Green Tea Suggests Cancer Cure (07/19/2005, United Press International) - http://www.nlm.nih.gov/medlineplus/news/fullstory_25846.html (*this news item will not be available after 08/18/2005)
Pomegranate Juice May Reduce Birth Defect (06/29/2005, United Press International) - http://www.nlm.nih.gov/medlineplus/news/fullstory_25484.html (*this news item will not be available after 07/29/2005)
Overviews
Antioxidant Vitamins (American Heart Association) - http://www.americanheart.org/presenter.jhtml?identifier=4452
Antioxidants: An Answer to Aging? (American Dietetic Association) - http://www.eatright.org/Public/NutritionInformation/index_2831.cfm
Specific Conditions
JAMA Patient Page: How Much Vitamin C Do You Need? (American Medical Association) - Links to PDF - http://jama.ama-assn.org/cgi/reprint/281/15/1460.pdf
Lycopene: An Antioxidant for Good Health (American Dietetic Association) - http://www.eatright.org/Public/NutritionInformation/92_8300.cfm
Selenium (National Institutes of Health, Office of Dietary Supplements) - http://ods.od.nih.gov/factsheets/selenium.asp
Vitamin A and Carotenoids (National Institutes of Health, Office of Dietary Supplements) - http://ods.od.nih.gov/factsheets/cc/vita.html
Vitamin E (National Institutes of Health, Office of Dietary Supplements) - http://ods.od.nih.gov/factsheets/vitamine.asp
Related Issues
Anti-Aging Therapies: Too Good to be True? (Mayo Clinic) - http://www.mayoclinic.com/invoke.cfm?id=HQ00233
Antioxidants and Cancer Prevention (National Cancer Institute) - http://www.cancer.gov/newscenter/pressreleases/antioxidants
Facing Cardiac Surgery? Ask Your Doctor about Vitamins and Supplements (Cleveland Clinic Foundation) - http://www.clevelandclinic.org/heartcenter/pub/guide/prevention/alternative/herbals_surgery.htm?inde...
Tea and Cancer Prevention (National Cancer Institute) - http://www.cancer.gov/newscenter/pressreleases/tea
Clinical Trials
ClinicalTrials.gov: Antioxidants (National Institutes of Health) - http://clinicaltrials.gov/search/intervention=antioxidants&recruiting=true
Research
Get Antioxidants from Food, Not Supplements (American Heart Association) - http://www.americanheart.org/presenter.jhtml?identifier=3023709
Vitamin E Supplements (National Center for Complementary and Alternative Medicine) - http://nccam.nih.gov/health/alerts/vitamine/vitamine.htm
Directories
Find a Nutrition Professional (American Dietetic Association) - http://www.eatright.org/Public/PublicDietitianDisclaimerAdvanced.htm
Organizations
Food and Nutrition Information Center - http://www.nal.usda.gov/fnic/
National Institutes of Health, Office of Dietary Supplements - http://dietary-supplements.info.nih.gov/
You may also be interested in these MedlinePlus related pages:
Vitamins and Minerals - http://www.nlm.nih.gov/medlineplus/vitaminsandminerals.html
Food and Nutrition - http://www.nlm.nih.gov/medlineplus/foodandnutrition.html
Date last updated: 20 July 2005
Topic last reviewed: 22 June 2005
Green tea suggests cancer cure
URL of this page: http://www.nlm.nih.gov/medlineplus/news/fullstory_25846.html (*this news item will not be available after 08/18/2005)
United Press International
By EVA A. SYLWESTER
Tuesday, July 19, 2005
WASHINGTON, Jul 18, 2005 (United Press International via COMTEX) -- New research reaffirms the potential value of green tea as a natural substance able to stop cancer before it starts.
"What we do in our conference every year is focus on what the scientists are talking about," said Jeffrey Prince, vice president for education and communications of the American Institute for Cancer Research.
Prince and others spoke at a news briefing at AICR's annual International Research Conference on Food, Nutrition and Cancer in Washington. He said this year's conference includes six separate presentations on the benefits of green tea -- and no tea companies were involved in the research.
The AICR also released the "New American Plate Cookbook," featuring recipes designed to promote smaller portion sizes and increased consumption of fruits and vegetables.
"The American Institute for Cancer Research recommends a mostly plant-based diet to people concerned with reducing cancer risk," Prince said.
Many plant-based foods are rich in anti-oxidants, which limit damage to cells and tissues that toxins and pollutants cause by slowing the rate of certain chemical reactions.
The active ingredient in green tea is a compound called epigallocatechin gallate, or EGCG, a stronger anti-oxidant than is contained in either vitamin C or E, according to an AICR fact sheet. Green tea is made from the same plant as black tea and oolong tea, but the leaves are not fermented during processing, which apparently preserves the plant's cancer-fighting compounds.
In a study using cancer cells in mice, Thomas Gasiewicz, a professor of environmental medicine at the University of Rochester in New York, found EGCG molecules bind to and inhibit the action of hsp90, a protein found disproportionately in cancer cells. Hsp90 also is found in smaller amounts in healthy cells throughout the body, suggesting EGCG could curb cancer development in numerous organs.
"Based on the animal studies, it's hard for me to believe that, at least at some dose, (EGCG) would not have a protective effect in the human population," Gasiewicz told reporters.
According to an AICR fact sheet, epidemiological studies have been conducted, mostly in Asian populations, that link green-tea consumption with a lower incidence of many different cancers. Gasiewicz said more research is required to pinpoint the exact dosage of green tea that provides cancer protection.
The benefits of green tea are underutilized in the U.S. population, the AICR fact sheet said. A telephone survey conducted by the organization, only 15 percent of Americans said they drink green tea every day, compared to 62 percent who drink soft drinks every day and 61 percent who drink coffee daily.
"People who drink cola or coffee on a regular basis might consider substituting green tea for one of those servings," Prince said, adding that for people who avoid caffeine, decaffeinated green tea is also available.
The AICR fact sheet said green tea generally has one-half to one-third of the caffeine in black tea and one-third to one-fourth of the caffeine in coffee.
Maggie Sheen, a food writer and recipe developer for AICR, told United Press International that getting green tea into the American diet requires no more than a trip to the supermarket, where at least two or three brands usually are available. Sheen suggested trying several brands to determine the best tasting variety, because green tea sometimes can seem bitter to the American tongue.
"We have such a sweet tooth and we're so used to putting sugar in everything that green tea is a shock to the palate," she said.
In contrast, average per-capita consumption of green tea in Japan and China is three to four 4 ounce cups per day.
In Japan, Sheen said, green tea is used as a flavoring in desserts, and the Japanese equivalent of "Grandma's chicken soup" is a porridge made from hot rice, leftover fish and green tea. She said she personally has experimented with adding green tea to foods such as cream cheese, pound cake and sorbet.
Prince said foods flavored with green tea may not provide all of the health benefits of a cup of the beverage, but nevertheless are worth a try and can help acclimate people to green tea's taste.
"The more you process plant foods, you lose some of the phytochemicals and some of the nutritional value," he noted.
--
Eva Sylwester is an intern for UPI Science News. E-mail: sciencemail@upi.com
Copyright 2005 by United Press International.
development of other products
We have also given consideration to the development of other products, such as
Protandim™ PET (a nutritional supplement for dogs and cats) and Protandim™ Multi (a vitamin and mineral compound).
We are only in the beginning stages of the research and development of these products and do not have a formulation for either of them. Consequently, we cannot offer any assurance that we will be able to develop or market these products.
http://www.sec.gov/Archives/edgar/data/849146/000102189005000083/lifeline3310510q.htm
Superoxide dismutase (SOD) is an antiinflammatory, antioxidant enzyme produced by the body that protects against joint inflammation.
Although SOD has been sold as a supplement, animal research shows that oral SOD is destroyed by the digestive system before it can repair damaged joints. Responsible scientists presume the same is true for humans, and there remains no evidence supporting the use of oral SOD supplements. Additional research with enteric-coated tablets of active SOD may provide new routes of administration in the future for use in inflammatory disorders.
Nevertheless, three minerals are needed by the body to make its own SOD: zinc, copper and manganese. Deficient levels of copper and manganese will lower SOD levels in animals. Moreover, copper-deficient humans have low SOD levels which increase with copper supplementation. Supplementing copper in patients with rheumatoid arthritis has also been reported to increase SOD levels.
http://www.diagnose-me.com/treat/T328819.html
[Possibilities of drug prophylaxis of adrenalin-induced glaucoma (an experimental study)]
[Article in Russian]
Alekseev VN, Martynova EB, Korelina VE, Materova IuV.
Experiments were carried out on 30 rabbits with adrenalin glaucoma. In 10 rabbits, intravenous adrenalin was paralleled by subconjunctival antioxidant superoxide dismutase (Erysod). Increase of intraocular pressure, changes of tonographic values, accumulation of lipid peroxidation products and alteration of the drainage zone morphology were observed in animals with adrenalin glaucoma. In animals administered erysod in parallel with adrenalin, tonometric and tonographic parameters were normal. The concentration of lipid peroxidation products in the blood was virtually normal in this group. Morphological studies showed no essential differences in the structure of the anterior chamber corner in the eyes of animals treated with erysod and in intact controls. The results demonstrate the possibility of preventing the development of primary open-angle glaucoma with erysod.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9720387&d...
Effect of age on superoxide dismutase activity of human trabecular meshwork
MA De La Paz and DL Epstein
Department of Ophthalmology, Duke University Medical Center, Durham, NC 27710, USA.
PURPOSE. It has been hypothesized that accelerated aging of the trabecular meshwork, perhaps because of oxidative damage, is involved in the pathogenesis of primary open angle glaucoma. The authors sought to evaluate the effect of donor age on the specific activity of superoxide dismutase and catalase in normal fresh human cadaver trabecular meshwork. METHODS. Total superoxide dismutase and catalase were assayed in tissue extracts generated from fresh human trabecular meshwork. Cadaver tissue was obtained from 19 donors (18 paired) of a wide age range (30 to 91 years). The assays were performed within 6 hours of enucleation and within 36 hours of donor death. Enzyme- specific activities were calculated using protein concentration of the extract as the denominator. RESULTS. Multiple regression analysis modeled with age and time from death until the beginning of the experiment was performed. The specific activity of superoxide dismutase declined with age (P = 0.00022; r2 = 0.67). There was no effect of age on catalase specific activity (P = 0.24; r2 = 0.16). The time from donor death until the beginning of the experiment was not a significant factor (P > 0.28). CONCLUSIONS. The specific activity of superoxide dismutase, but not catalase, demonstrates an age-dependent decline in normal cadaver human trabecular meshwork. The potential role of superoxide dismutase in primary open angle glaucoma, a disorder of the aging trabecular meshwork, warrants further investigation.
http://www.iovs.org/cgi/content/abstract/37/9/1849
Lifeline Therapeutics’ Director of Science is the Co-discoverer of Superoxide Dismutase (SOD)
Dr. Joe McCord, the preeminent SOD scientist is part of the Lifeline management team
In 1969, Dr. Joe McCord, together with Irwin Fridovich, discovered SOD, spawning an avalanche of scientific research and affirmation. For this monumental achievement, he and Fridovich were awarded the prestigious Elliot Cresson Medal for "for their seminal work, singly and together, of discovering and elucidating the biology of free radical reactions and their enzymatic controls in living organisms, as well as the pathology of free radical diseases." Previous recipients of the award, founded in 1848, have included such notable scientists and inventors as Alexander Graham Bell, Orville Wright, Henry Ford, Wernher von Braun, Pierre and Marie Curie, and Andrei Sakharov. Dr. McCord therefore stands in distinguished company for greatly impacting lives for generations to come.
Dr. McCord's additional awards are too numerous to list, but they include a Lifetime Achievement Award from the Oxygen Society for outstanding contributions to the field of free radical biology and medicine. Dr. McCord has served as the President of the International Society of Antioxidants in Nutrition and Health (ISANH). He was also the Chairman of the 2nd International Conference on Superoxide Dismutases: Recent Advances and Clinical Applications, which was held at the Institute Pasteur in Paris. In addition, Dr. McCord has been published in many scientific journals including the greatly-respected New England Journal of Medicine.
Dr. McCord served as an Executive Editor for the Archives of Biochemistry and Biophysics; Serves on the Editorial Board for the Journal of Biochemistry, and the Editorial Board of Inflammation Research Interests: The Chemistry and Pathophysiology of Superoxide and Related Free Radicals, especially with regard to oxidant/antioxidant balance in such diseases as AIDS, Down's Syndrome, cancer, and diabetes.
Dr. McCord currently serves as the Head for the Division of Biochemistry and Molecular Biology at the Webb-Waring Institute for Cancer, Aging, and Antioxidant Research. As the discoverer of SOD, paramount SOD researcher, and author of numerous studies and articles on SOD, Dr. McCord is the most highly-regarded expert in the field of Superoxide Dismutases.
Dr. Joe McCord Publications (short list)….
Some "Citation Classics":
• J.M. McCord and I. Fridovich, Superoxide Dismutase: an Enzymic Function for Erythrocuprein (Hemocuprein), J. Biol. Chem. 244: 6049-6055 (1969).
• J.M. McCord, Free Radicals and Inflammation: Protection of Synovial Fluid by Superoxide Dismutase, Science 185:529-531 (1974).
• J.M. McCord, Oxygen-Derived Free Radicals in Post-Ischemic Tissue Injury, New Eng. J. Med. 312:159-163 (1985).
Some Recent Publications:
• M.P. Look, K. Krämer, J.K. Rockstroh, J.M. McCord and L. Packer, High-dose nutraceuticals in human immunodeficiency virus-disease. An understudied option? Curr. Topics Nutraceut.Res. 1: 1-16 (2003).
• W.H. Cerwinka, C.F. Krieglstein, C.R. Ross, J.M. McCord and D.N. Granger, Superoxide mediates endotoxin-induced platelet-endothelial cell adhesion in intestinal venules. Am. J. Physiol. Heart Circ. Physiol. 284: H535- H541 (2003).
• I.N. Hines, J.M. Hoffman, H. Scheerens, B.J. Day, H. Harada, K.P. Pavlick, S. Bharwani, R. Wolf, B. Gao, S.C. Flores, J.M. McCord and M.B. Grisham, Regulation of post-ischemic liver injury following different durations of ischemia, Am. J. Physiol.Gastrointest Liver Physiol. 284:G536-G545 (2003).
• B. Gao, S.C. Flores, J.A. Leff, S.K. Bose, and J.M. McCord, Synthesis and anti-inflammatory activity of a chimeric recombinant superoxide dismutase: SOD2/3, Am. J. Physiol. Lung Cell Mol. Physiol. 284: L917-L925 (2003).
• E.S.M. Ng, D. Jourd'heuil, J.M. McCord, D. Hernandez, M. Yasui, D. Knight, and P. Kubes, Enhanced S-nitroso-albumin formation from inhaled NO during ischemia/reperfusion Circ. Res. 94:559-565 (2004).
• H. Harada, I. Hines, S. Flores, B. Gao, J. McCord, H. Scheerens, and M. Grisham, Role of NADPH oxidase-derived superoxide in reduced size liver ischemia and reperfusion injury, Arch. Biochem. Biophys. 423: 103-108 (2004).
• C.S. Bonder, D. Knight, D. Hernandez-Saavedra, J.M. McCord and P. Kubes, Chimeric SOD2/3 inhibits at the endothelial-neutrophil interface to limit vascular dysfunction in ischemia/reperfusion, Am. J. Physiol. Gastrointest Liver Physiol. In press (2004).
About Superoxide Dismutase…
The first line of defense that the body has against superoxide free radicals is the enzyme known as Superoxide Dismutase (SOD) which is existent in three forms and considered the body's most effective antioxidant.
The importance of SOD is so paramount for the protection of our cells that animals cannot live without it. In brief, SOD keeps oxygen under control. SOD activity has been determined to be directly correlated to aging and lifespan determination.
Medquest reports that "SOD may in fact be the most powerful life-extending discovery of our time." However, SOD production declines with age, allowing for a multitude of age-related conditions to set in. SOD must therefore be enhanced, starting in our mid-to-late twenties, in order to combat the ravages of free radicals. SOD must also be increased in tandem with Catalase (CAT) and Glutathione Peroxidase (GPX) as part of a coordinated defense and repair system. SOD, CAT and GPX enhancement is the sole mission of Lifeline Therapeutics, Inc.
About Lifeline Therapeutics Corp…
Lifeline is a privately held, Denver-based company formed to manufacture, market and distribute nutraceutical supplements that promote "Healthy Life Expectancy." Lifeline is presently focusing exclusively on unique antioxidant therapies under its Protandim brand. The therapies center on the body's primary defense mechanism against oxidative stress - the natural antioxidant enzymes, Superoxide Dismutase (SOD), Catalase (CAT), and Glutathione Peroxidase (GPX). Discussions have commenced regarding license agreements and other collaborative arrangements in order to aggressively place its Protandim product candidates into the global marketplace.
NOTIFICATION PURSUANT TO SECTION 6 OF DSBUEA and 21 CFR (j 14$9
http://www.fda.gov/ohrms/dockets/dockets/97s0162/97s-0162-let16091-vol142.pdf
Thanks. Understood.
Dr Joe McCord discussing free radicals
Our bodies need iron; it's fundamental to the creation and maintenance of our blood supply, notes Joe McCord, PhD, a professor of biochemistry and medicine at Denver's University of Colorado Health Sciences Center. But the twin miracles of evolution and modern science have given us too much of a good thing. Back when we were wandering hunters and gatherers, our bodies hoarded iron whenever possible because we never knew if we'd get more. Now, however, we can get enough iron from well-balanced diets and supplements. Yet our bodies still accumulate the metal as if there were a shortage.
Sullivan first hypothesized that stored iron may contribute to heart attacks back in 1981, just a couple of years before the cholesterol study unleashed an anti-fat frenzy. Since then, he believes, the cholesterol police have been leading us in the wrong direction. "I think the role of cholesterol in heart disease is vastly overrated, Sullivan says, "and I question whether lowering it will do much good."
If you believe Sullivan, what will work is decreasing your iron levels by giving up a cup or two of blood every few months. But while becoming a regular donor may be admirable, does it really help your health?
Good fat gone bad
According to the conventional view, a buildup of cholesterol collects in our blood vessels as plaque, narrowing the arteries and, in the worst cases, eventually cutting off the flow of blood, causing a heart attack. But anti-iron advocates believe the metal plays an integral role in this process.
McCord has some ideas about why this would be so. Fat and cholesterol are natural parts of our diet and metabolism, he says. But when you add iron, these otherwise harmless substances oxidize, becoming deadly killers.
"When you leave a stick of butter out, it goes rancid," McCord says. "That may happen in the body as well. With oxidation, the properties of the fat or cholesterol change, forming plaque that builds up in the arteries."
The main problem is free radicals, unstable oxygen molecules that our bodies create just by living and breathing. These molecules have only one electron instead of the normal two, and they sneak up on other oxygen molecules and steal their electrons; this sets off a veritable crime wave of electron theft, damaging cells throughout your body and accelerating the aging process. You can lessen the impact with foods containing antioxidant vitamins such as C and E. Iron, on the other hand, may exacerbate the oxidation process and release more free radicals, helping turn harmless fat and cholesterol into blood vessel-dogging plaque.
It isn't just the heart that's harmed in this process, McCord claims. The general increase in free radicals and the resulting rancidity of the body's fat may damage cells throughout the body, making them more vulnerable to all manner of disease and infection. That's because cell boundaries, or "walls," are made of fat, and the increased oxidation caused by iron compromises cellular integrity, negatively affecting every organ in which they're located. This would mean that high iron levels not only increase the risk of heart attack, they also heighten the likelihood of fatality and a more difficult recovery, as well as worsening the effects of other illnesses.
http://www.findarticles.com/p/articles/mi_m1608/is_n7_v14/ai_20946893#continue
23-Jun-2005 3:55pm
Regulation FD Disclosure
ITEM 7.01. Regulation FD.
Lifeline Therapeutics, Inc. (the "Company") intends to disclose the following information to certain investors and other members of the public on or after June 24, 2005:
For the period between June 1, 2005 and June 17, 2005 the Company's total gross sales exceeded $1.5 million, without allowances for returns and defective product. The Company believes that the increase in its gross sales during this time period is primarily attributable to increased exposure in the national media. The Company does not expect either this increased exposure in the national media or the current rate of sales to continue for the immediate future.
More information about the Company and Protandim™ can be found on our website at www.protandim.com.
http://biz.yahoo.com/e/050623/lflt.ob8-k.html
I invested a few days after the PT Live airing. If the product(s) are effective, and I believe they are, the share price should rise over time. I have been taking Protandim for 16 days. I did not really expect to feel any different and have not noticed any specific physical changes. However, I do have a general increase in energy.
Any reason why the stock has pulled back to the current levels or did it just run ahead of itself in general due to ABC Primetime?
Vany
The SP is going to move alot with very little influence do to the low float. As a result of the Prime Time exposure, the earnings should show a remarkable increase.
Are you a customer, shareholder or both.
S
Lifeline Therapeutics Launches Protandim, A First-of-its-Kind Antioxidant Therapy
First Antioxidant Therapy Proven to Eliminate Age-Related Oxidative Stress, Featured on ABC Primetime Live
Lifeline Therapeutics, Inc. (OTCBB:LFLT), dedicated to developing products that help people live better, healthier and longer lives by fighting oxidative damage in the body, today announced Protandim -- a first-of-its-kind, patent-pending antioxidant therapy that turns "on" the body's catalytic system to naturally produce key antioxidants inside the cell, where they are needed most. Unlike other antioxidants that require high doses and are not absorbed well within the body, Protandim is the first dietary supplement proven to restore age-related oxidative stress to levels seen in someone 20 years old or younger by increasing the body's own catalytic antioxidant defense and repair system. Protandim was positively featured on ABC Primetime Live on June 2.
"Everyone is looking for ways to manage the effects of aging and extend their youth," said Bill Driscoll, president and CEO of Lifeline Therapeutics. "Unfortunately, most products currently on the market are ineffective and unsubstantiated. With Protandim there is now a scientifically based antioxidant therapy that induces the production of the body's own natural antioxidants and extends one's healthy life expectancy."
The announcement of Protandim comes on the heels of a recent U.S. scientific study on aging, led by Dr. Peter Rabinovitch and his colleagues at the University of Washington School of Medicine. They found that increasing the amount of antioxidants naturally produced in the body, such as Catalase (CAT), can dramatically slow the aging process, destroy free radicals and promote healthier life. The study prolonged the lives of laboratory mice by 20 percent using a technique that boosts their natural antioxidant defenses. In addition to increased life expectancy, the mice had healthier heart muscle tissue, indicating that CAT helped protect them from age-related heart problems. The study indicates that stimulating the body's own production of natural antioxidants, such as the way Protandim revs up the body's natural antioxidant defenses, is the best approach to combating oxidative stress and the aging process itself.
A New Approach to Oxidative Stress
Oxidative stress is the harmful condition that occurs when there are excessive free radicals or a marked decrease in antioxidant levels, causing the body to age -- similar to how a car rusts or an apple turns brown. It has been scientifically demonstrated that high levels of oxidative stress negatively impact the body's healthy life expectancy. Particularly in the United States and Western world, the last ten years of life tend to be plagued by various degenerative health issues and illnesses often associated with oxidative stress.
Protandim offers a new, proven approach to fight oxidative stress -- the ability to increase the body's levels of two essential natural antioxidant enzymes: Superoxide Dismutase (SOD) and Catalase (CAT). Unfortunately, the body's production of these natural antioxidant enzymes declines with age, allowing for a plethora of age-related concerns to have an upper hand in the conditions we associate with aging.
Traditional antioxidant supplements, like Vitamin C and E, are "consumable" antioxidants. They are taken to fight oxidants and the resulting damage, which is oxidative stress. They fight oxidants on a 1-to-1 level and are then consumed or used up and flushed out of the system. Protandim is a fundamentally different approach. Like a catalytic converter in a car, Protandim induces the body to increase the production of its own natural catalytic antioxidant defense system and thus provides highly efficient antioxidant protection. The botanical ingredients in Protandim induce the cells to produce more of their own antioxidant catalysts. Rather than eliminating oxidants 1-for-1, these catalysts are tens of thousands of times more effective because they destroy oxidants without being consumed or used up themselves. Combined, they can eliminate up to one million oxidants per second.
Backed by Science
Protandim is co-formulated by Dr. Joe McCord, the co-discoverer of SOD in 1969. Dr. McCord is Director of Science for Lifeline Therapeutics, the developer and distributor of Protandim. In 1997, Dr. McCord was awarded the prestigious Elliot Cresson Medal from The Franklin Institute for "his seminal work of discovering and elucidating the biology of free radical reactions and their enzymatic controls in living organisms, as well as the pathology of free radical diseases." Through its awards program, The Franklin Institute seeks to provide public recognition and encouragement of excellence in science and technology. The list of Franklin Institute laureates reads like a "Who's Who" in the history of 19th and 20th century science, including Alexander Graham Bell, Pierre and Marie Curie, Rudolf Diesel, Thomas Edison, Niels Bohr, Max Planck, Albert Einstein and Stephen Hawking. To date, 101 Franklin Institute laureates also have been honored with 103 Nobel Prizes. Dr. McCord received a Lifetime Achievement Award from the Society for Free Radical Biology and Medicine for outstanding contributions to the field. Dr. McCord serves as President of the International Society of Antioxidants in Nutrition and Health (ISANH).
"Throughout my entire career, I've been focused on antioxidants. Protandim is unlike other antioxidants or supplements available because it works within the cells to optimize the body's natural enzymes," said Dr. Joe McCord. "The pre-clinical and clinical studies have clearly demonstrated the effectiveness and impact of Protandim. In fact, in clinical studies, Protandim restored oxidative stress to the level of someone younger than 20 years old."
Lifeline Therapeutics has completed pre-clinical trials and clinical trials with the University of Colorado Health Sciences Center. In clinical studies, participants were evaluated at 0, 30, and 120 days with blood tests measuring oxidative stress via TBARS, as well as levels of the body's natural enzymes, Superoxide Dismutase (SOD) and Catalase (CAT). Initial data from the pre-clinical and clinical studies have substantiated that Protandim can significantly reduce oxidative stress and effectively eliminate age-related oxidative stress.
Product Availability
Protandim is available online at www.Protandim.com and by calling 1-8-PROTANDIM (1-877-682-6346). A 30-day supply can be purchased for $49.95.
About Lifeline Therapeutics
Lifeline Therapeutics, Inc. is a publicly traded company (OTCBB:LFLT) based in Denver, Colorado, that is dedicated to developing and marketing evidenced-based pharmaceutical products that show advanced efficacy in dealing with oxidative-stress related diseases -- including cancer and diabetes -- as well as nutraceutical and cosmeceutical products that demonstrate vastly superior antioxidant protection and anti-aging results. The Company's scientific platform is based on breakthrough research involving the body's natural antioxidant enzymes, Superoxide Dismutase (SOD) and Catalase (CAT). These enzymes are thousands of times more powerful than consumable antioxidants and can increase "Healthy Life Expectancy" through the avoidance or diminishing of age-related disease conditions. Lifeline has developed a patent-pending composition, Protandim, that has been proven to be the first and only dietary supplement to simultaneously increase these two enzymes and reduce oxidative stress levels to those of a 20-year-old or younger. To underscore the Company's commitment to higher quality of life and healthy life expectancy, Lifeline Therapeutics has pledged 10% of its pre-tax profits to support orphanages and other global humanitarian needs. For more information, visit www.Protandim.com.
Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable common law. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Other important factors that the Company believes might cause such differences include the Company's limited cash flow and the rapid development of technology, lack of liquidity for the Company's common stock, working capital shortages, the length of time for scientific advances to reach the market (if they ever reach the market), among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company's filings with the Securities and Exchange Commission.
CONTACT:
Ogilvy Public Relations Worldwide Aliza Rothman, 303-634-2672 aliza.rothman@ogilvypr.com
http://www.genengnews.com/news/bnitem.aspx?name=543085XSL_NEWSML_TO_NEWSML_WEB.xml
Nice job Steeley. In looking for next "earnings" release date, 10QSB, which should be revealing, I think the next pop could happen around the first week in August? ...and float, (make that sink) lower until then unless they release a PR about spectcular sales before then. Whatchya think?
New Product Fights Aging From Within
Protandim is the first antioxidant therapy proven to fight oxidative stress - a key component of aging.
Looking for the fountain of youth? One company may have found it. Lifeline Therapeutics has introduced Protandim, the first antioxidant therapy proven to fight oxidative stress - a key component of aging.
The baby boomer generation is devoting considerable energy to slowing the aging process. Now, Lifeline Therapeutics has introduced Protandim, the first antioxidant therapy proven to fight oxidative stress - a key component of aging - by increasing the body's own natural defenses.
Consumers gulp vitamin C and E pills, take ginkgo biloba and even spray human growth hormone into their mouths to fend off illness and age. The problem, researchers say, is that the body can't digest the volume of these substances needed to really make an impact.
Protandim increases the body's catalytic antioxidant defense system, which to the present knowledge is the first attempt to do that in human beings. It’s the first product that elevates your bodies own antioxidant defense system.
Doctors think this is an important tool that will enable scientists to now study with much greater ability to control this balance between oxidants and antioxidants. Dr. Jay Olshansky, an expert on aging and mortality at the University of Illinois at Chicago, would not comment directly on Lifeline's supplement, but said, "If they can up-regulate the body's own production of free-radical scavengers, they may be onto something."
http://toronto.fashion-monitor.com/news.php/beauty/2005060803youth_product
Protandim Dietary Supplement to Be Released in February 2005
2004-11-19 - Lifeline Therapeutics, Inc.
--------------------------------------------------------------------------------
DENVER, Nov 19, 2004 (BUSINESS WIRE) -- Lifeline Therapeutics, Inc. (LFLT) announced today that Protandim, a scientifically-based anti-aging dietary supplement is scheduled to be released in February 2005.
Protandim is not an antioxidant, but its patent-pending formulation induces the body to produce more of its own natural antioxidant enzymes, thereby utilizing biology not chemistry to fight oxidation.
The body's primary antioxidant is Superoxide Dismutase (SOD) and its levels have previously been shown to be directly correlated to aging in 14 different species, including humans. Species with the highest amounts of SOD live the longest and any increase in SOD corresponds to an increase in lifespan. According to separate studies conducted by John Tower, a molecular biologist at the University of Southern California, and by molecular biologist John Phillips of the University of Guelph in Ontario, the extended time of life was youth. Old age was postponed.
SOD was discovered by Dr. Joe McCord and his associate in 1969, for which they received the prestigious Elliot Cresson medal, previously awarded to Henry Ford, the Wright brothers, Madam Curie and other notable figures that have made great advances for humanity. Since Dr. McCord's discovery, there have been approximately 25,000 scientific studies and/or articles about SOD, thereby confirming its importance within the scientific community. Dr. McCord now serves as LFLT's Director of Science.
Protandim will initially be sold directly by LFLT through an undated Website (currently under development) and call center operations. The company plans to evaluate and consider distribution alternatives for additional countries and also consider other possible channels of distribution. These other channels of distribution may also include a health practitioner distribution system.
After very promising pre-clinical results, Protandim is currently undergoing human trials at the renowned Webb-Waring Institute of Cancer, Aging and Antioxidant Research (Webb-Waring). Although the duration of the studies will continue for a period that extends past the projected product release timeframe, there is already enough data to demonstrate the safety and efficacy of the Protandim product.
ABOUT PROTANDIM
It has been thought that antioxidants, such as vitamins C and E and many other antioxidants found in fresh fruits and vegetables, serve to limit oxidative stress (as measured by lipid peroxidation) in vivo. However, recent studies have shown that supplemental vitamins produced no effect on biomarkers of lipid peroxidation in healthy men with low fruit and vegetable intake (whether smokers or non-smokers). LFLT believes that Protandim offers a better approach - to upregulate the body's natural family of antioxidant enzymes: Superoxide Dismutase (SOD), Catalase (CAT) and Glutathione Peroxidase (GPX). Protandim allows these enzymes to be produced where they are most needed - within the cells where oxidative stress actually occurs. This is in stark contrast to traditional antioxidant supplements, which have to pass significant digestive and absorption barriers and simply can't be consumed in the quantities needed to protect the body against the damage caused by oxidative stress. Not hampered by quantity, digestive and absorption constraints, Protandim acts as a catalyst to cause the body to increase the production of its own antioxidant defense system.
ABOUT LIFELINE THERAPEUTICS
Lifeline Therapeutics, Inc. is a publicly-traded (LFLT) company based in Denver, Colorado, that is dedicated to the manufacture, marketing and distribution of therapies that promote "Healthy Life Expectancy." LFLT is initially focusing exclusively on unique antioxidant products under its Protandim brand. LFLT's business plan incorporates an array of product candidates for nutraceutical, pharmaceutical and cosmeceutical applications. These therapies center on the body's primary defense mechanism against oxidative stress - the co-regulation of the natural antioxidant enzymes, Superoxide Dismutase (SOD), Catalase (CAT), and Glutathione Peroxidase (GPX).
For more information, please contact Bill Driscoll at info@lifelinenutraceuticals.com
Protandim components
milk thistle (silybum marianum) seed
Neurotrophic and neuroprotective effects of milk thistle (Silybum marianum) on neurons in culture.
Kittur S, Wilasrusmee S, Pedersen WA, Mattson MP, Straube-West K, Wilasrusmee C, Lubelt B, Kittur DS.
Department of Neurology, SUNY Upstate Medical University, Syracuse, NY 13210, USA. kitturs@upstate.edu
Herbal products are being increasingly used as dietary supplements and therapeutic agents. However, much more research must be performed in order to determine the biological basis for their putative clinical effects. We tested the effects of milk thistle (Silybum marianum) extract on the differentiation and survival of cultured neural cells. Milk thistle enhanced nerve growth factor (NGF)-induced neurite outgrowth in PC-12 neural cells and prolonged their survival in culture. Milk thistle extract also protected cultured rat hippocampal neurons against oxidative stress-induced cell death. Our data demonstrate that milk thistle extract can promote neuronal differentiation and survival, suggesting potential benefits of chemicals in this plant on the nervous system.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_....
ashwagandha (withania somnifera) root
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.
Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY.
Department of Internal Medicine, National Taiwan University College of Medicine, Taipei. andrew@ha.mc.ntu.edu.tw
Curcumin (diferuloylmethane), a yellow substance from the root of the plant Curcuma longa Linn., has been demonstrated to inhibit carcinogenesis of murine skin, stomach, intestine and liver. However, the toxicology, pharmacokinetics and biologically effective dose of curcumin in humans have not been reported. This prospective phase-I study evaluated these issues of curcumin in patients with one of the following five high-risk conditions: 1) recently resected urinary bladder cancer; 2) arsenic Bowen's disease of the skin; 3) uterine cervical intraepithelial neoplasm (CIN); 4) oral leucoplakia; and 5) intestinal metaplasia of the stomach. Curcumin was taken orally for 3 months. Biopsy of the lesion sites was done immediately before and 3 months after starting curcumin treament. The starting dose was 500 mg/day. If no toxicity > or = grade II was noted in at least 3 successive patients, the dose was then escalated to another level in the order of 1,000, 2,000, 4,000, 8,000, and 12,000 mg/day. The concentration of curcumin in serum and urine was determined by high pressure liquid chromatography (HPLC). A total of 25 patients were enrolled in this study. There was no treatment-related toxicity up to 8,000 mg/day. Beyond 8,000 mg/day, the bulky volume of the drug was unacceptable to the patients. The serum concentration of curcumin usually peaked at 1 to 2 hours after oral intake of crucumin and gradually declined within 12 hours. The average peak serum concentrations after taking 4,000 mg, 6,000 mg and 8,000 mg of curcumin were 0.51 +/- 0.11 microM, 0.63 +/- 0.06 microM and 1.77 +/- 1.87 microM, respectively. Urinary excretion of curcumin was undetectable. One of 4 patients with CIN and 1 of 7 patients with oral leucoplakia proceeded to develop frank malignancies in spite of curcumin treatment. In contrast, histologic improvement of precancerous lesions was seen in 1 out of 2 patients with recently resected bladder cancer, 2 out of 7 patients of oral leucoplakia, 1 out of 6 patients of intestinal metaplasia of the stomach, I out of 4 patients with CIN and 2 out of 6 patients with Bowen's disease. In conclusion, this study demonstrated that curcumin is not toxic to humans up to 8,000 mg/day when taken by mouth for 3 months. Our results also suggest a biologic effect of curcumin in the chemoprevention of cancer.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_....
bacopa monnieri aerial part
Chronic effects of Brahmi (Bacopa monnieri) on human memory.
Roodenrys S, Booth D, Bulzomi S, Phipps A, Micallef C, Smoker J.
Department of Psychology, University of Wollongong, Woolongong, Australia. steven_roodenrys@uow.edu.au
A study is reported on the effects of Brahmi (Bacopa monniera) on human memory. Seventy-six adults aged between 40 and 65 years took part in a double-blind randomized, placebo control study in which various memory functions were tested and levels of anxiety measured. There were three testing sessions: one prior to the trial, one after three months on the trial, and one six weeks after the completion of the trial. The results show a significant effect of the Brahmi on a test for the retention of new information. Follow-up tests showed that the rate of learning was unaffected, suggesting that Brahmi decreases the rate of forgetting of newly acquired information. Tasks assessing attention, verbal and visual short-term memory and the retrieval of pre-experimental knowledge were unaffected. Questionnaire measures of everyday memory function and anxiety levels were also unaffected.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_....
turmeric (curcuma longa) rhizome
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.
Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY.
Department of Internal Medicine, National Taiwan University College of Medicine, Taipei. andrew@ha.mc.ntu.edu.tw
Curcumin (diferuloylmethane), a yellow substance from the root of the plant Curcuma longa Linn., has been demonstrated to inhibit carcinogenesis of murine skin, stomach, intestine and liver. However, the toxicology, pharmacokinetics and biologically effective dose of curcumin in humans have not been reported. This prospective phase-I study evaluated these issues of curcumin in patients with one of the following five high-risk conditions: 1) recently resected urinary bladder cancer; 2) arsenic Bowen's disease of the skin; 3) uterine cervical intraepithelial neoplasm (CIN); 4) oral leucoplakia; and 5) intestinal metaplasia of the stomach. Curcumin was taken orally for 3 months. Biopsy of the lesion sites was done immediately before and 3 months after starting curcumin treament. The starting dose was 500 mg/day. If no toxicity > or = grade II was noted in at least 3 successive patients, the dose was then escalated to another level in the order of 1,000, 2,000, 4,000, 8,000, and 12,000 mg/day. The concentration of curcumin in serum and urine was determined by high pressure liquid chromatography (HPLC). A total of 25 patients were enrolled in this study. There was no treatment-related toxicity up to 8,000 mg/day. Beyond 8,000 mg/day, the bulky volume of the drug was unacceptable to the patients. The serum concentration of curcumin usually peaked at 1 to 2 hours after oral intake of crucumin and gradually declined within 12 hours. The average peak serum concentrations after taking 4,000 mg, 6,000 mg and 8,000 mg of curcumin were 0.51 +/- 0.11 microM, 0.63 +/- 0.06 microM and 1.77 +/- 1.87 microM, respectively. Urinary excretion of curcumin was undetectable. One of 4 patients with CIN and 1 of 7 patients with oral leucoplakia proceeded to develop frank malignancies in spite of curcumin treatment. In contrast, histologic improvement of precancerous lesions was seen in 1 out of 2 patients with recently resected bladder cancer, 2 out of 7 patients of oral leucoplakia, 1 out of 6 patients of intestinal metaplasia of the stomach, I out of 4 patients with CIN and 2 out of 6 patients with Bowen's disease. In conclusion, this study demonstrated that curcumin is not toxic to humans up to 8,000 mg/day when taken by mouth for 3 months. Our results also suggest a biologic effect of curcumin in the chemoprevention of cancer.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_....
Lifeline Therapeutics, Inc. Selects Ogilvy Public Relations Worldwide as Agency of Record
Denver Anti-aging Company Enlists Ogilvy PR for Brand-Building Launch Program
DENVER, CO, FEB. 15, 2005. Lifeline Therapeutics, Inc., (OTTB: LFLT) has selected the Ogilvy Public Relations consumer marketing practice to execute a comprehensive brand-building public relations effort. Ogilvy PR's Denver office will spearhead the program.
"We selected Ogilvy PR for their in-depth understanding of our business and knowledge of the anti-aging market," stated Bill Driscoll, President and CEO of LFLT. "Ogilvy PR will play a pivotal role in establishing a whole new category of anti-aging products designed to increase healthy life expectancy."
The first product, based on LFLT's proprietary Protandim technology that enhances the body's primary antioxidant enzymes, will be introduced within the next few weeks. The highly-anticipated product has been heralded by researchers as a significant breakthrough in antioxidant therapy and has received much global media attention over the past 18 months.
Paul Myhill, LFLT's Vice President and Director of Marketing, said, "Since our inception, we have aligned ourselves with the best professionals and counsel that industry has to offer. Ogilvy is certainly one of the most recognized and trusted names in the marketing communications industry. Our revolutionary product requires such an elite, reputable, global company."
ABOUT OGILVY PUBLIC RELATIONS WORLDWIDE…
Ogilvy Public Relations Worldwide is a foremost global marketing communications firm, with offices in more than 60 cities around the world. Ogilvy PR has specialties in consumer marketing, corporate (B2B), health & medical, social marketing, technology, public affairs, government relations and entertainment. Through its subsidiary, Feinstein Kean Healthcare, Ogilvy PR provides communication consulting to biotechnology companies. The Holmes Report has named Ogilvy Public Relations Worldwide as the "2003 International Agency of the Year," marking the fourth consecutive year the firm has been awarded such status. Ogilvy PR is part of the WPP Group, the world's largest marketing communications company (NASDAQ: WPPGY, www.wpp.com).
Ogilvy Public Relations
http://www.ogilvypr.com/index.cfm
Client List
Consumer Marketing
American Red Cross
Berry Burst Cheerios
Celestial Seasonings
cheaptickets.com
Disney
DuPont™
Hellman's
Kraft
Johnsonville Sausage
LG Electronics
LensCrafters
Lipton
Pizza Hut
Promise
Slim-Fast
Sunglass Hut
Target Stores
Unilever
Corporate
Ajilon
American Home Mortgage
BP
Cendant
CFA Institute
Deloitte
FM Global
Hudson Highland Group
Jackson Hewitt
Lazard Freres & Co. LLC
MasterCard
Warburg Pincus
Weida Communications
Wells Fargo
Health and Medical
Berlex
Bristol-Myers Squibb
Dey
Ethicon
GlaxoSmithKline
Merck
NPS
Ortho-Biotech
Pfizer
Roche
Schering Plough
Public Affairs
American Chemistry Council
Berlex
Department of Homeland Security
Discovery
DuPont™
EarthLink
Intelsat
MasterCard
United Way
Social Marketing
Centers for Disease Control and Prevention
Centers for Medicare & Medicaid Services
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Child Health and Human Development (NICHD)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Cancer Institute (NCI)
National Human Genome Research Institute (NHGRI)
National Eye Institute
National Library of Medicine
Epilepsy Foundation
Technology
DuPont
Fuego
iBiquity
Integic
LG Electronics
Level 3
MailFrontier
USInternetworking
"Protandim"
because it "promotes tandem" up-regulation of Superoxide dismutase, catalase and glutathionne peroxidase (SOD, CAT, GPX) - the body's antioxidant enzymes
Company website
http://www.lifelinetherapeutics.com/index.htm
Faq
http://www.protandim.com/faq.htm
---------------------------------------------------------------------------------------------------------------
Does a New Pill Contain the Fountain of Youth?
Protandim May Slow Aging Process by Increasing Enzymes That Fight Free Radicals
Jun. 2, 2005 - Dr. Joe McCord's latest research may unravel the mystery of aging. And if he succeeds, the answer could come in the form of a little yellow pill called Protandim.
The University of Colorado at Denver biochemistry professor has conducted decades of experiments into a special class of enzymes in the cell that some hope have the potential of extending lives and possibly preventing chronic diseases like cancer, diabetes and heart disease.
Much of his work has centered on oxidative stress -- which increases with age. TBARS, which are a measure of oxidative stress, can also be a rough indicator of a person's actual age.
But, McCord has found that the ingredients in Protandim lowered the test subject's level of oxidative stress.
"They all are reduced to the level of oxidative stress that one would expect, frankly, in a newborn. Or a very young child,' he said.
Dangerous Radicals
To be sure, there have been other supposed "miracle" drugs and treatments that never delivered on their promise to delay or even stop human aging. But McCord, research director in the company that makes Protandim, believes this pill might be different.
To understand how Protandim works, you have to first understand how aging occurs.
Aging is "a slow progression of oxidative stress," McCord said. Much of oxidative stress comes from the basic function of eating.
As cells burn food, they also release toxic chemicals known as "free radicals" which cause cell damage and consequently -- oxidative stress.
The body fights back by making two anti-oxidant enzymes -- Catalase and SOD. But as people get older, those enzymes can get overwhelmed.
For a long time, scientists thought that anti-oxidant vitamins like C and E could lower oxidation, but many experts now believe they aren't effective.
Protandim, McCord said, is much more powerful. Tests on both mice and humans have already shown that it revs up the body's manufacture of those enzymes -- thereby reducing the presence of those harmful free radicals.
However, McCord cannot say at this point whether or not Protandim could lead to a longer life. Experiments to see if mice live longer are about to get under way.
Studies have not yet been conducted to determine whether Protandim can prevent disease.
"Right now, all we know is that this preparation decreases oxidative stress. Oxidative stress is not a disease, just like aging is not, in itself, a disease," he said. "But it's something that accompanies, and is attached to, many disease processes."
The Power of Enzymes
McCord said Protandim could be "something that will tell us a lot more about how we age, what happens biochemically. And maybe how we can slow it down."
And there is some other promising independent evidence that seems to back him up.
Dr. Douglas Wallace of the University of California at Irvine conducted an experiment and found that mice that have been genetically engineered to produce more catalase, one of the enzymes that Protandim increases, lived about 20 percent longer.
Wallace believes that with better techniques the lifespan for humans can eventually be extended too. "We might be able to increase the lifespan by 50 percent. And of course if that was a human being, then that might be in the order of 130 to 150 years," he said.
Dr. Michael Brownlee, who heads the Center for Research on Diabetic Complications at Albert Einstein Medical College, conducted another experiment involving another enzyme boosted by Protandim called SOD.
He tested diabetic mice and found their wounds simply don't heal -- a problem common for diabetics. But when another diabetic mouse that was genetically engineered to have more SOD was wounded, it healed much better.
"Even though they were diabetic, they healed, just like the normal," he said. "It is a breakthrough."
Secret Formula
Protandim may seem to have incredible potential, but its roots are actually very humble.
It is a combination of five plant ingredients. Two of them are pretty commonplace -- green tea and turmeric, a spice used in Indian cooking. The others, among them withania somnifera and silybum marianum, are more exotic.
"There's a huge human experience with each of these ingredients," McCord said. "They've been used often in traditional medicine in India and China and many other cultures in some cases for centuries and centuries."
And that experience, plus his tests on human subjects so far, indicates that the ingredients are safe.
And so, ancient Eastern healing and modern Western medicine may soon be working together.
High oxidative stress is associated with more than aging. It's been linked to hundreds of illnesses, from cancer to heart disease to Parkinson's and even depression.
But McCord said: "We make no claims about curing any disease, or preventing any disease. We hope that when enough studies are done, perhaps such claims might be made in the future."
Because Protandim is composed of herbal ingredients with a long history of use, it is being marketed as a nutraceutical, and does not require FDA approval.
However, the company is planning further clinical studies in three to four months to assess Protandim in both diabetes and heart disease, which will be submitted for substantiation.
-------------------------------------------------------------------------------------------------------------
Colo. Doctor Invents 'Anti-Aging' Pill
Protandim Claims To Slow Down Aging Process
POSTED: 10:08 am MDT June 3, 2005
UPDATED: 11:10 am MDT June 3, 2005
DENVER -- A Colorado doctor has invented a supplement that he says slows the aging process and could possibly prevent diseases. The pill is called Protandim, a natural supplement that he claims can change the chemistry of the body.
The supplement makes you healthier, but you don't feel any changes, said Protandim's manufacturer.
One of the trial participants 7NEWS spoke with said that besides a slight peak in energy, he didn't notice any changes. But Leigh Severance swears by this new "anti-aging" pill. He said he'll take it until the day he dies but jokes that if the pill really works, he'll be around for a long time.
Severance is 66 years old, partially retired and lives on a golf course. But he said, on the inside he's really 22 years old. But he doesn't attribute his youthful feeling to a midlife crisis or his Porsche.
Severance is taking Protandim, an antioxidant supplement he says eliminates age-related oxidative stress. Oxidative stress is when you have too many free radicals in your system and not enough antioxidants.
"When you have too many oxidants, cells become damaged, all of the main classes of molecules get oxidized and damaged," said Dr. Joe McCord said.
McCord, who is with the University of Colorado Health Sciences Center, formulated Protandim.
"Oxidative stress is probably the main biochemical marker of the aging process, So if want to know how old an organism is, you can measure oxidative stress level and it will give you an idea," said McCord.
He said the pill can lower that level of oxidative stress by revving up your natural antioxidants. And that, in turn, makes people like Severance 22 years old, McCord said.
Or at least when it comes to his oxidative stress levels.
"It's getting rid of millions of free radicals," said Severance. He hopes it's helping him live longer.
"I've told my kids that they need to be taking it," he said.
McCord said oxidative stress often accompanies many diseases like cancer, diabetes and Alzheimer's disease. So now that he says his supplement helps healthy people, he plans on studying how it will affect those already suffering with diseases and how healthy people may be able to avoid getting sick in the future.
More Information:
Protandim is available online at Protandim.com or by calling (877) 682-6346 (1-8-Protandim)
Welcome to the new Lifeline Therapeutics message board!
Post and say what you like...no censorship here!
Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
44
|
Created
|
06/12/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |